A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant.

Humans Brain Neoplasms / pathology Prognosis Homozygote Residual Volume Sequence Deletion Mutation Astrocytoma / genetics Isocitrate Dehydrogenase / genetics
astrocytoma IDH-mutant lower-grade glioma mitoses resection residual volume

Journal

Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829

Informations de publication

Date de publication:
08 2023
Historique:
revised: 13 07 2023
received: 13 04 2022
accepted: 22 07 2023
medline: 31 8 2023
pubmed: 28 7 2023
entrez: 28 7 2023
Statut: ppublish

Résumé

The distinction between CNS WHO grade 2 and grade 3 is instrumental in choosing between observational follow-up and adjuvant treatment for resected astrocytomas IDH-mutant. However, the criteria of CNS WHO grade 2 vs 3 have not been updated since the pre-IDH era. Maximal mitotic activity in consecutive high-power fields corresponding to 3 mm Seventy-one per cent of the samples had <6 mitoses per 3 mm Mitotic activity and post-surgical residual volume can be combined to evaluate the prognosis for patients with resected astrocytomas IDH-mutant. Patients with <6 mitoses per 3 mm

Identifiants

DOI: 10.1111/nan.12928 PMID: 37503540
pubmed: 37503540
doi: 10.1111/nan.12928
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12928

Informations de copyright

© 2023 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

Références

Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. The Lancet. 2012;379(9830):1984-1996. doi:10.1016/S0140-6736(11)61346-9
Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170-186. doi:10.1038/s41571-020-00447-z
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106
WHO Classification of Tumours Editorial Board. WHO classification of tumours of the central nervous system. 5th ed. Internat. Agency for Research of Cancer; 2021.
Bell EH, Zhang P, Shaw EG, et al. Comprehensive genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. JCO. 2020;38(29):3407-3417. doi:10.1200/JCO.19.02983
Fleming JL, Pugh SL, Fisher BJ, et al. Long-term report of a comprehensive molecular and genomic analysis in NRG oncology/RTOG 0424: a phase II study of radiation and Temozolomide in high-risk grade II glioma. JCO Precis Oncol. 2021;5(5):1397-1407. doi:10.1200/PO.21.00112
van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985-990. doi:10.1016/S0140-6736(05)67070-5
Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1521-1532. doi:10.1016/S1470-2045(16)30313-8
van den Bent MJ, Brandes AA, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic Oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. JCO. 2013;31(3):344-350. doi:10.1200/JCO.2012.43.2229
Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. JCO. 2013;31(3):337-343. doi:10.1200/JCO.2012.43.2674
Lombardi G, Barresi V, Castellano A, et al. Clinical management of diffuse low-grade gliomas. Cancer. 2020;12(10):3008. doi:10.3390/cancers12103008
Albuquerque LAF, Almeida JP, de Macêdo Filho LJM, Joaquim AF, Duffau H. Extent of resection in diffuse low-grade gliomas and the role of tumor molecular signature-a systematic review of the literature. Neurosurg Rev. 2021;44(3):1371-1389. doi:10.1007/s10143-020-01362-8
Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129(6):867-873. doi:10.1007/s00401-015-1438-8
Pekmezci M, Rice T, Molinaro AM, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017;133(6):1001-1016. doi:10.1007/s00401-017-1690-1
Shirahata M, Ono T, Stichel D, et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018;136(1):153-166. doi:10.1007/s00401-018-1849-4
Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(3):603-608. doi:10.1007/s00401-020-02127-9
Appay R, Dehais C, Maurage CA, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019;noz124. doi:10.1093/neuonc/noz124
Yang RR, Shi Z, Zhang Z, et al. IDH mutant lower grade (WHO grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol. 2020;30(3):541-553. doi:10.1111/bpa.12801
Wijnenga MMJ, French PJ, Dubbink HJ, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2018;20(1):103-112. doi:10.1093/neuonc/nox176
McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):700-708. doi:10.1227/01.NEU.0000325729.41085.73
Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg. 2013;118(6):1157-1168. doi:10.3171/2013.1.JNS121
Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article. JNS. 2012;117(6):1039-1052. doi:10.3171/2012.8.JNS12393
Roelz R, Strohmaier D, Jabbarli R, et al. Residual tumor volume as best outcome predictor in low grade glioma - a nine-years near-randomized survey of surgery vs biopsy. Sci Rep. 2016;6(1):32286. doi:10.1038/srep32286
Idbaih A, Marie Y, Lucchesi C, et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer. 2007;122(8):1778-1786. doi:10.1002/ijc.23270
Labussiere M, Boisselier B, Mokhtari K, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014;83(13):1200-1206. doi:10.1212/WNL.0000000000000814
Di Stefano AL, Picca A, Saragoussi E, et al. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. Neuro Oncol. 2020;22(11):1614-1624. doi:10.1093/neuonc/noaa121
Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469-474. doi:10.1038/nature26000
Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015;129(4):585-596. doi:10.1007/s00401-015-1398-z
Colman H, Giannini C, Huang L, et al. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating Astrocytomas. Am J Surg Pathol. 2006;30(5):657-664. doi:10.1097/01.pas.0000202048.28203.25
Weller M, Weber RG, Willscher E, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015;129(5):679-693. doi:10.1007/s00401-015-1409-0
Yoda RA, Marxen T, Longo L, et al. Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma. J Neuropathol Exp Neurol. 2019;78(11):1002-1010. doi:10.1093/jnen/nlz082
Franceschi E, Tosoni A, Bartolini S, et al. Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. Eur J Cancer. 2020;137:10-17. doi:10.1016/j.ejca.2020.06.018
Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499-2508. doi:10.1056/NEJMoa1407279
Delgado-López PD, Corrales-García EM, Martino J, Lastra-Aras E, Dueñas-Polo MT. Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies. Clin Transl Oncol. 2017;19(8):931-944. doi:10.1007/s12094-017-1631-4
Choi J, Kim SH, Ahn SS, et al. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma. Sci Rep. 2020;10(1):2086. doi:10.1038/s41598-020-59089-x
Patel SH, Bansal AG, Young EB, et al. Extent of surgical resection in lower-grade gliomas: differential impact based on molecular subtype. AJNR am J Neuroradiol. 2019;40(7):1149-1155. doi:10.3174/ajnr.A6102
Mandonnet E, Duffau H. An attempt to conceptualize the individual onco-functional balance: why a standardized treatment is an illusion for diffuse low-grade glioma patients. Crit Rev Oncol Hematol. 2018;122:83-91. doi:10.1016/j.critrevonc.2017.12.008
Al-Tamimi YZ, Palin MS, Patankar T, et al. Low-grade glioma with foci of early transformation does not necessarily require adjuvant therapy after radical surgical resection. World Neurosurg. 2018;110:e346-e354. doi:10.1016/j.wneu.2017.10.172
Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-718. doi:10.1007/s00401-010-0781-z
Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. JCO. 2009;27(25):4150-4154. doi:10.1200/JCO.2009.21.9832
von Deimling A, Ono T, Shirahata M, Louis D. Grading of diffuse astrocytic gliomas: a review of studies before and after the advent of IDH testing. Semin Neurol. 2018;38(1):019-023. doi:10.1055/s-0038-1636430
Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11(4):341-347. doi:10.1215/15228517-2009-025
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma Multiforme. Science. 2008;321(5897):1807-1812. doi:10.1126/science.1164382
Yan H, McLendon R, Kos I, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):9-773. doi:10.1056/NEJMoa0808710
Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474. doi:10.1007/s00401-009-0561-9
Cimino PJ, Holland EC. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. Neuro Oncol. 2019;21(6):819-821. doi:10.1093/neuonc/noz052
Mirchia K, Snuderl M, Galbraith K, Hatanpaa KJ, Walker JM, Richardson TE. Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas. Acta Neuropathol Commun. 2019;7(1):121. doi:10.1186/s40478-019-0778-3
Wijnenga MMJ, French PJ, Dubbink HJ, et al. Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. J Neurooncol. 2018;139(2):349-357. doi:10.1007/s11060-018-2867-8
Richardson TE, Walker JM. The prognostic significance of RB and PI3K pathway alterations in IDH-mutant grade II/III astrocytomas. J Neuropathol Exp Neurol. 2020;79(9):1019-1023. doi:10.1093/jnen/nlaa083
Lu VM, O'Connor KP, Shah AH, et al. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. J Neurooncol. 2020;148(2):221-229. doi:10.1007/s11060-020-03528-2

Auteurs

Suzanne Tran (S)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neuropathology, Paris, France.

Alice Thomas (A)

Department of Radiation Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.

Ilyes Aliouat (I)

Department of Neurosurgery, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Paris, France.

Carine Karachi (C)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Department of Neurosurgery, Paris, France.

Fernando Lozano (F)

AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France.

Karima Mokhtari (K)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neuropathology, Paris, France.

Caroline Dehais (C)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France.

Loïc Feuvret (L)

AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Department of Radiotherapy, Paris, France.

Catherine Carpentier (C)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France.

Marine Giry (M)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris, France.

Abiba Doukani (A)

Sorbonne Université, Inserm, UMS Production et Analyse des données en Sciences de la vie et en Santé, PASS, Plateforme Post-génomique Pitié-Salpêtrière, P3S, Paris, France.

Julie Lerond (J)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris, France.
Sorbonne Université, AP-HP, Paris, France.

Yannick Marie (Y)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris, France.

Marc Sanson (M)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France.
Sorbonne Université, AP-HP, Paris, France.
Department of Neuropathology, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.

Ahmed Idbaih (A)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France.

Alexandre Carpentier (A)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Department of Neurosurgery, Paris, France.

Khê Hoang-Xuan (K)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France.

Mehdi Touat (M)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neurology 2, Paris, France.

Laurent Capelle (L)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Department of Neurosurgery, Paris, France.

Franck Bielle (F)

Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire Pitié-Salpêtrière, DMU Neurosciences, Department of Neuropathology, Paris, France.
Sorbonne Université, AP-HP, Paris, France.
Department of Neuropathology, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
ORCID: 0000-0001-6564-6388

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A threshold for mitotic activity and...
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › A threshold for mitotic activity and...
questionsmedicales.fr › Diagnostic › Pronostic › A threshold for mitotic activity and...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Homozygote › A threshold for mitotic activity and...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques respiratoires › Capacité pulmonaire totale › Capacité résiduelle fonctionnelle › Volume résiduel › A threshold for mitotic activity and...
questionsmedicales.fr › Phénomènes génétiques › Mutagenèse › Délétion de séquence › A threshold for mitotic activity and...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › A threshold for mitotic activity and...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › A threshold for mitotic activity and...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Alcohol oxidoreductases › NAD (+) and NADP (+) dependent Alcohol oxidoreductases › Isocitrate dehydrogenases › A threshold for mitotic activity and...